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ABSTRACT
Introduction: Chronic kidney disease (CKD) is
associated with symptoms that can significantly reduce
the quality of life (QoL) of patients. Patient-reported
outcome measures (PROMs) may facilitate the
assessment of the impact of disease and treatment on
the QoL, from a patient perspective. PROMs can be
used in research and routine clinical practice.
Methods and analysis: A systematic review of
studies evaluating the measurement properties of
PROMs in adults with CKD will be conducted.
MEDLINE, EMBASE, PsycINFO and CINAHL Plus will
be systematically searched from inception. Hand
searching of reference lists and citations of included
studies will be carried out. 2 reviewers will
independently screen the titles and abstracts of all the
studies retrieved during the systematic search to
determine their eligibility. The COnsensus-based
Standards for the selection of health Measurement
Instruments (COSMIN) checklist will be used to
appraise the methodological quality of the selected
studies following the full-text review. Data on the study
population, questionnaire characteristics and
measurement properties will be extracted from the
selected papers. Finally, a narrative synthesis of
extracted data will be undertaken.
Ethics and dissemination: Ethical permissions are
not required for this study as data from published
research articles will be used. Findings will be
disseminated through publication in a peer-reviewed
journal and presented at conferences. This systematic
review will provide a comprehensive assessment of the
measurement properties of PROMs currently available
for use in adult patients with CKD and present
evidence which may inform the selection of measures
for use in research and clinical practice.
Trial registration number: CRD42016035554.
INTRODUCTION
Chronic kidney disease (CKD) is deﬁned
as the existence of kidney damage (ie,
pathological abnormalities or markers of
damage) for 3 months or more; and/or an
estimated glomerular ﬁltration rate (eGFR)
<60 mL/min/1.73 m2 for 3 months or
longer, with or without kidney damage.1
CKD affects up to 16% of adults in the
UK2 and is associated with poor outcomes,
with a high proportion of patients dying
before reaching end-stage renal disease.3 4
According to the UK Department of Health,
the total cost of providing renal care by the
National Health Service (NHS) was £1.64
billion in 2009–2010.5 Aside from these overt
costs, the NHS bears other costs accrued
from treating associated conditions while
patients and caregivers have to contend with
possible loss of income.5
Patients with CKD often suffer simultan-
eously from multiple symptoms related to
the condition or side effects of their medical
treatment.6 These clusters of symptoms may
exert an adverse effect not only on their
physical health but also on their psycho-
logical and emotional well-being; giving rise
Strengths and limitations of this study
▪ A key strength of this systematic review is that
multiple databases will be searched by multiple
independent reviewers, with no language or pub-
lication date restrictions, thus minimising the
risk of selection bias.
▪ A further strength is that the methodological
quality of selected studies will be evaluated
using the validated COSMIN checklist.
▪ This review will include studies relating to
chronic kidney disease in adults and exclude
studies of all other kidney conditions and chil-
dren, this decision has been taken to ensure the
results are focused on the study research
question.
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to what is described as a ‘symptom burden’.7 A review by
Almutary et al8 identiﬁed 30 symptoms associated with
CKD, with 5 symptoms (fatigue, drowsiness, pain, prur-
itus and dry skin) particularly common in all stages.8
They concluded that the overall symptom burden was
high regardless of disease stage.8 This symptom burden
is now acknowledged as the most important predictor of
diminished health-related quality of life (HRQoL) in
patients with CKD.9
In a clinical context, HRQoL refers to the manner in
which the physical, emotional and social well-being of
an individual is affected by a disease and/or its treat-
ment.10 HRQoL can be measured using self-
administered, validated questionnaires also known as
patient-reported outcome measures (PROMs).11 12
PROMs have numerous applications in clinical trials
and routine clinical settings. They are employed in clini-
cal trials as measures of effectiveness and pharmaceuti-
cal companies may use PROM data to support product
approvals and labelling claims.13 PROMs can aid the
reporting of serious adverse events due to drug toxici-
ties14 and trial data can also inﬂuence clinical care and
health policy.15 16
In routine clinical practice, PROMs are mainly used as
tools for benchmarking and hospital performance
assessment.17 However, PROMs also have the potential
to assist in the delivery of personalised care.11 17–21
Currently, primary and secondary care records in the
UK are being linked together such that patient informa-
tion is more readily available to clinicians when
required.22 The integration of patient-reported outcome
(PRO) data with other routinely collected clinical data
could provide an opportunity for revolutionising the UK
healthcare system by facilitating the delivery of stratiﬁed
medicine, enhancing clinical audits and assisting with
the designing of pragmatic trials.12 21
Given the vast array of PROMs in existence,23 the
selection of an appropriate measure for any purpose
requires the careful consideration of their measurement
properties in order to derive any meaningful beneﬁt
from their application. It is crucial that such decisions
are backed by the best evidence available, preferably
from a recent systematic review.12
A scoping search identiﬁed two relevant systematic
reviews namely: a 2010 review by Gibbons and Fitzpatrick
and a 2012 review by Wyld et al.24 25 Although both
reviews presented evidence of the measurement proper-
ties of PROMs in CKD, there is a realistic possibility that
more relevant research work has been performed since
their publication.26 In addition, both studies had eligibil-
ity criteria which might have excluded potentially rele-
vant studies.24 25 Gibbons and Fitzpatrick restricted their
review to studies published in English language and con-
ducted in English-speaking populations within the UK,
North America or Australasia. They also excluded studies
with sample sizes <50.24 Wyld et al25 focused on studies
that assessed preference-based (utility) measures exclud-
ing studies that evaluated HRQoL measures that did not
have a utility component and only included studies con-
ducted in other languages if they provided an English
abstract.
Therefore, after considering the issues above, we con-
cluded that a full systematic review is required. The aim
of this systematic review will be to evaluate the measure-
ment properties of PROMs currently available for use in
adults with CKD.
This review will include studies that assess the measure-
ment properties of generic, utility as well as disease-speciﬁc
PROM instruments in patients at any stage of CKD.
Recent methodological advances and guidelines27–29 will
be employed to ensure that the most up-to-date and
robust evidence is obtained.
METHODS AND ANALYSIS
Design
The protocol has been registered with PROSPERO
(registration number CRD42016035554). It was develo-
ped using the Preferred Reporting Items for Systematic
Review and Meta-Analysis Protocols (PRISMA-P)
checklist.29
The review will be conducted and reported in compli-
ance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines.30
Search strategy
The following electronic databases will be systematically
searched from inception: MEDLINE (Ovid), EMBASE
(Ovid), PsycINFO (Ovid) and CINAHL Plus (EBSCO).
Literature search results will be uploaded to Endnote X7
(Thomson Reuters). There will be no publication period
or language restrictions.27 The UK Renal Registry will be
searched and expert recommendations from members of
the review team will be followed up to help identify any
additional measures currently under development.
The search strategy for MEDLINE was developed in
consultation with an information specialist at the
Institute of Applied Health Research, University of
Birmingham. Two existing search ﬁlters, the sensitivity
search ﬁlter developed by Terwee et al31 and the Oxford
PROM ﬁlter,32 were combined with key terms for renal
disease generated by the review team. The MEDLINE
search strategy was adapted for use and tested on all the
databases (see online supplementary appendix for the
full search strategy).
Selection of studies
To be considered for selection, an article must focus on
PROMs used speciﬁcally for measuring QoL and/or
CKD symptoms (the constructs of interest). In addition,
the following inclusion and exclusion criteria will be
applied.
Inclusion criteria
1. Articles reporting PROM development in all CKD
populations.
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2. Articles explicitly reporting the assessment of one or
more psychometric properties for PROM(s) in all
CKD populations.
3. Articles reporting cross-cultural validation of PROMs
in all CKD populations.
Exclusion criteria
1. Clinician-assessed instruments.
2. Instrument development studies solely in patients
with acute kidney injury.
3. Instruments developed solely for use in patients
below 18 years of age.
4. Trials or studies evaluating the effectiveness of inter-
ventions where a PROM questionnaire is used as an
end point.
5. Editorials, reviews and conference abstracts.
All titles and abstracts will be screened by two
independent reviewers (OLA and TK/AG).
Full-text articles will be obtained for studies that
potentially meet the eligibility criteria and will again be
independently reviewed by the investigators (OLA and
TK/AG).
Abstracts that do not provide the reviewers with
enough information to make a decision will be taken
forward for full-text screening, thus minimising the risk
of missing potentially eligible articles.
Reasons for exclusion at the full-text stage of screening
will be recorded. At any stage, if the reviewers are
unable to reach a consensus, a third reviewer will be
consulted (MC/DK). Hand searching of reference lists
and citations of included papers will be conducted.
The process of selection will be summarised using a
PRISMA ﬂow diagram.
Appraisal of the methodological quality of selected studies
All eligible papers will be independently appraised by
two reviewers using the COnsensus-based Standards for
the selection of health Measurement Instruments
(COSMIN) checklist.28 33 The COSMIN checklist is a
validated critical appraisal tool designed for the system-
atic evaluation of the methodological quality of studies
of the measurement properties of health measurement
instruments.28
The COSMIN checklist employs a four-point rating
scale which allows the rating of items relating to each
measurement property as ‘excellent’, ‘good’, ‘fair’ or
‘poor’ depending on the methodological quality of each
study. If a study meets all the requirements for an item,
it is rated ‘excellent’ for that item. Conversely, if a study
fails to meet the requirements for an item, it is given a
lower rating commensurate to its quality.28
The overall quality rating for each measurement prop-
erty is determined using the ‘worst score counts’
method.28 This means that the methodological quality
for each measurement property will be determined by
taking the lowest rating of its items.
The following measurement properties as deﬁned by
Mokkink et al34 will be evaluated:
1. Reliability—‘The proportion of the total variance in
the measurements which is because of “true” differ-
ences among patients’.34
2. Internal consistency—‘The degree of the inter-
relatedness among the items’.34
3. Measurement error—‘The systematic and random
error of a patient’s score that is not attributed to true
changes in the construct to be measured’.34
4. Content validity—‘The degree to which the content
of an HR-PRO instrument is an adequate reﬂection
of the construct to be measured’.34
5. Construct validity—‘The degree to which the scores
of an HR-PRO instrument are consistent with hypoth-
eses (for instance with regard to internal relation-
ships, relationships to scores of other instruments, or
differences between relevant groups) based on the
assumption that the HR-PRO instrument validly mea-
sures the construct to be measured’.34
6. Cross-cultural validity—‘The degree to which the per-
formance of the items on a translated or culturally
adapted HR-PRO instrument are an adequate reﬂec-
tion of the performance of the items of the original
version of the HR-PRO instrument’.34
7. Criterion validity—‘The degree to which the scores
of an HR-PRO instrument are an adequate reﬂection
of a “gold standard”’.34 The consensus by the
COSMIN panel was that no gold standard exists for
PROMs even though some authors consider widely
used instruments as ‘gold standards’. An exception
made by the panel is the comparison of a shortened
measure to the original longer version, in which case,
the original version can be regarded as the gold
standard.28 33
8. Responsiveness—‘The ability of an HR-PRO instru-
ment to detect change over time in the construct to
be measured’.34
Data extraction
Data from selected studies will be extracted independ-
ently by two reviewers, using a data collection form, with
disagreements resolved through discussion and, if neces-
sary, consultation with a third reviewer. Extracted data
will be presented in tables. Where appropriate, the
results will be presented in separate sections/tables for
instruments assessed in predialysis, dialysis and patients
who had kidney transplant.
Data on the following will be extracted:
1. characteristics of the study population (including
age, gender, ethnicity and stage of CKD);
2. questionnaire characteristics (including name/
version, language, scoring method, domains, number
of items);
3. evidence regarding the measurement properties of
the questionnaire;
4. setting and purpose for which questionnaire is
administered, interpretability and operational
characteristics such as patient acceptability, and feasi-
bility of administration for staff will also be reported.
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Data synthesis
Two sets of criteria will be used to assess the quality of the
measurement properties:27 35
▸ The quality criteria proposed by Terwee et al35 will be
used to rate the results of studies of measurement properties
as ‘positive’, ‘indeterminate’ or ‘negative’.35
▸ The modiﬁed criteria reported in Terwee 201127 (ori-
ginally proposed by the Cochrane Back Review
Group)36 will be used to synthesis ﬁndings on the
measurement property of each PROM across studies
in order to ascertain the level of evidence for each
instrument while taking into consideration the meth-
odological quality of the selected studies. This overall
level of evidence will be rated as ‘strong’, ‘moderate’,
‘limited’, ‘conﬂicting’ or ‘unknown’.27
DISSEMINATION
Findings will be disseminated through publication in a
peer-reviewed journal and presented at conferences.
DISCUSSION
We acknowledge that studies will evaluate differing meas-
urement properties; therefore, evidence might be
limited or unavailable for some measurement properties.
This systematic review will present a comprehensive
assessment of the measurement properties of PROMS
currently available for use in adult patients with CKD
and provide vital evidence which may inform the selec-
tion of measures for use in research and clinical
practice.
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